Stock STIM NEURONETICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Neuronetics, Inc.

Equities

STIM

US64131A1051

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
1.92 USD +1.05% Intraday chart for Neuronetics, Inc. -11.93% -33.79%
May. 15 Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents CI
May. 14 William Blair Upgrades Neuronetics to Outperform From Market Perform MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents
CI
Earnings Flash (STIM) NEURONETICS Reports Q1 Revenue $17.4M
MT
Neuronetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Neuronetics, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal Year 2024
CI
Neuronetics, Inc. Announces the Publication of Significant Clinical Findings in Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation
CI
Neuronetics Shares Climb 15% After FDA Cleared Depression Treatment for Adolescents Aged 15 to 21
DJ
Neuronetics Gets US FDA Clearance for Treatment of Adolescents with Depression; Shares Rise
MT
Neuronetics, Inc. Announces Clearance from the U.S. Food and Drug Administration for NeuroStar Advanced Therapy
CI
Neuronetics, Inc. Announces 5-Year Exclusive Partnership with Transformations Care Network
CI
Earnings Flash (STIM) NEURONETICS Reports Q4 Revenue $20.3M
MT
Neuronetics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Neuronetics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024
CI
North American Morning Briefing : S&P 500 Futures -2-
DJ
Neuronetics Launches Latest Evolution in Its Trakstar® Patient Data Management System
CI
Neuronetics, Inc. Revises Earnings Guidance for the Fourth Quarter and Full Year of 2023
CI
Neuronetics Receives 510(K) Clearance for Neurosite Coil Placement Accessory
CI
Neuronetics, Inc. Elevates Depression Treatment with Cutting-Edge Technology Advancements
CI
Earnings Flash (STIM) NEURONETICS Reports Q3 Revenue $17.9M
MT
Neuronetics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Neuronetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. STIM Stock
  4. News Neuronetics, Inc.
  5. Highlights